Martin Graham, PhD is the Chief Executive Officer of the Empire Discovery Institute.  Martin joined EDI in 2019 and has over 30 years of pharmaceutical industry experience in the development of small molecule drugs and biologics.  Most recently he was the founder and CEO of KinderPharm and PKPD Biosciences before their acquistion by Synteract/Syneos.  

 

Prior to KinderPharm, he served as a scientific advisor to the Harrington Discovery Institute and was the VP of Development at TetraLogic Pharmaceuticals a VC backed oncology company.  He held positions of increasing responsibility at Sterling-Winthrop, Sanofi, Centocor, and Johnson & Johnson and was actively involved in the development and commercialization of multiple therapeutics including Oxalipaltin, Remicade, Elitek and Stelara.  He is a pharmacologist by training